| Name | Title | Contact Details |
|---|
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
Advanced Environmental Testing And Abatement, Inc is a Waterloo, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CARBONDALE CLINIC AND SURGERY is a Carbondale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.